Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.42
-0.49 (-2.59%)
At close: Jul 14, 2026, 4:00 PM EDT
18.56
+0.14 (0.76%)
After-hours: Jul 14, 2026, 6:05 PM EDT
Avalo Therapeutics Revenue
In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%.
Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
16,411.15
Revenue / Employee
$1,788
Employees
33
Market Cap
968.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.00K | -382.00K | -86.62% |
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | 6.75M | -278.03K | -3.96% |
| Dec 31, 2018 | 7.03M | -20.78M | -74.73% |
| Dec 31, 2017 | 27.81M | 26.66M | 2,312.26% |
| Dec 31, 2016 | 1.15M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 82.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Kura Oncology | 71.64M |
| Lexicon Pharmaceuticals | 69.64M |
| Janux Therapeutics | 13.73M |
| Inventiva | 7.94M |
| DBV Technologies | 5.74M |
AVTX News
- 7 days ago - Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum - GlobeNewsWire
- 8 days ago - Avalo Therapeutics initiated with an Outperform at Leerink - TheFly
- 18 days ago - Avalo Therapeutics to join Russell 2000, Russell 3000 - TheFly
- 18 days ago - Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 21 days ago - Avalo Therapeutics Appoints Ron Philip to Board of Directors - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics advances AVTX-010 - TheFly
- 4 weeks ago - Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics initiated with a Buy at BofA - TheFly